Roche Appeals Negative EMEA Decision For Tarceva Pancreatic Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.